<!DOCTYPE html>
<html lang="en-us">
  <head>
	<meta name="generator" content="Hugo 0.85.0" />
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    
    <title>fallingstar-Daily-rss | Fallingstar Daily R</title>
    <link rel="stylesheet" href="/css/style.css" />
    <link rel="stylesheet" href="/css/fonts.css" />
    <link href="//cdn.bootcss.com/highlight.js/9.12.0/styles/github.min.css" rel="stylesheet">

  </head>

  <body>
    <nav class="header">
      <div class="banner">
<a href="/" class="text">
&Ffr;&Afr;&Lfr;&Lfr;&Ifr;&Nfr;&Gfr;&Sfr;&Tfr;&Afr;&Rfr; &Dfr;&Afr;&Ifr;&Lfr;&Yfr; &Rfr;
</a>
</div>

      <div class="head-meta">
      
        <span>fallingstar-Daily-rss</span>
        <span>2024-09-28</span>
      
      </div>
    </nav>


<div class="container">
<main class="list">

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39327770/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240927184334&amp;v=2.18.0.post9&#43;e462414">Assessing the hierarchical beta-binomial model as a basic information sharing tool in basket trials</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39327770-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240927184334-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The majority of statistical methods to share information in basket trials are based on a Bayesian hierarchical model with a common normal distribution for the logit-transformed response rates. The methods are of varying complexity, yet they all use this basic model. Generally, complexity is an obstacle for the application in clinical trials and that includes the use of the logit-transformation. The transformation complicates the model and impedes a direct interpretation of the &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39327798/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240927184334&amp;v=2.18.0.post9&#43;e462414">Mechanisms behind the high mortality rate in chronic Chagas cardiomyopathy: Unmasking a three-headed monster</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39327798-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240927184334-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Chagas disease is a neglected tropical disease caused by the parasite Trypanosoma cruzi. Chronic Chagas cardiomyopathy (CCC), the most severe form of target organ involvement in Chagas disease, is characterized by a complex pathophysiology and a unique phenotype that differentiates it from other cardiomyopathies, highlighting its worse prognosis compared to other aetiologies of heart failure. The three pathophysiological mechanisms with the largest impact on this differential mortality &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39327800/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240927184334&amp;v=2.18.0.post9&#43;e462414">Bending the rules: A novel approach to laryngeal surgery in a body donor study</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39327800-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240927184334-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: The sMAC system effectively addresses challenges associated with transoral laryngeal surgery. Ongoing development aims to overcome current limitations of the system and prepare first clinical &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39327800/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Bending the rules: A novel approach to laryngeal surgery in a body donor study</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39327800-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: The sMAC system effectively addresses challenges associated with transoral laryngeal surgery. Ongoing development aims to overcome current limitations of the system and prepare first clinical &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39328074/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240927184334&amp;v=2.18.0.post9&#43;e462414">Meeting the Needs of People With Severe Quadriplegia in the 21st Century: The Case for Implanted Brain-Computer Interfaces</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39328074-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240927184334-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: Most importantly, the gap in digital equality fundamentally undermines the basic human rights of people with severe &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39328074/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Meeting the Needs of People With Severe Quadriplegia in the 21st Century: The Case for Implanted Brain-Computer Interfaces</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39328074-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: Most importantly, the gap in digital equality fundamentally undermines the basic human rights of people with severe &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39329071/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240927184334&amp;v=2.18.0.post9&#43;e462414">Effectiveness of the Medical Chatbot PROSCA to Inform Patients About Prostate Cancer: Results of a Randomized Controlled Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39329071-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240927184334-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS AND CLINICAL IMPLICATIONS: With the introduction of the PROSCA chatbot, we created and evaluated an innovative, evidence-based AI health information tool as an additional source of information for PC. Our RCT results showed significant benefits of the chatbot in reducing patients' information needs and enhancing their understanding of PC. This easy-to-use AI tool provides accurate, timely, and accessible support, demonstrating its value in the PC diagnosis process. Future &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39329071/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Effectiveness of the Medical Chatbot PROSCA to Inform Patients About Prostate Cancer: Results of a Randomized Controlled Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39329071-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS AND CLINICAL IMPLICATIONS: With the introduction of the PROSCA chatbot, we created and evaluated an innovative, evidence-based AI health information tool as an additional source of information for PC. Our RCT results showed significant benefits of the chatbot in reducing patients' information needs and enhancing their understanding of PC. This easy-to-use AI tool provides accurate, timely, and accessible support, demonstrating its value in the PC diagnosis process. Future &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39329251/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240927184334&amp;v=2.18.0.post9&#43;e462414">A Negatively Curved Nanographene with Four Embedded Heptagons</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39329251-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240927184334-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Negatively curved nanographenes are considered as cutouts of three-dimensional fully sp²-hybridized carbon allotropes such as Schwarzites. Here we present the synthesis of a C(76) cut-out of the Schwarzite 8-4-1-p proposed by Lenosky et al. and investigate its optical as well as electrochemical properties. Furthermore, supramolecular interactions with fullerenes C(60) and C(70) were &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39329251/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">A Negatively Curved Nanographene with Four Embedded Heptagons</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39329251-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Negatively curved nanographenes are considered as cutouts of three-dimensional fully sp²-hybridized carbon allotropes such as Schwarzites. Here we present the synthesis of a C(76) cut-out of the Schwarzite 8-4-1-p proposed by Lenosky et al. and investigate its optical as well as electrochemical properties. Furthermore, supramolecular interactions with fullerenes C(60) and C(70) were &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39329430/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240927184334&amp;v=2.18.0.post9&#43;e462414">Exploring PKG signaling as a therapeutic avenue for pressure overload, ischemia, and HFpEF</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39329430-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240927184334-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    INTRODUCTION: Heart failure (HF) is a complex and heterogeneous syndrome resulting from any diastolic or systolic dysfunction of the cardiac muscle. In addition to comorbid conditions, pressure overload, and myocardial ischemia are associated with cardiac remodeling which manifests as extracellular matrix (ECM) perturbations, impaired cellular responses, and subsequent ventricular &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39329430/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Exploring PKG signaling as a therapeutic avenue for pressure overload, ischemia, and HFpEF</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39329430-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    INTRODUCTION: Heart failure (HF) is a complex and heterogeneous syndrome resulting from any diastolic or systolic dysfunction of the cardiac muscle. In addition to comorbid conditions, pressure overload, and myocardial ischemia are associated with cardiac remodeling which manifests as extracellular matrix (ECM) perturbations, impaired cellular responses, and subsequent ventricular &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39329449/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240927184334&amp;v=2.18.0.post9&#43;e462414">DNA methylation as a new tool for the differential diagnosis between T-LBL and lymphocyte-rich thymoma</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39329449-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240927184334-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    T-lymphoblastic lymphoma (T-LBL) and thymoma are two rare primary tumors of the thymus deriving either from T-cell precursors or from thymic epithelial cells, respectively. Some thymoma subtypes (AB, B1, and B2) display numerous reactive terminal deoxynucleotidyl transferase-positive (TdT^(+)) T-cell precursors masking epithelial tumor cells. Therefore, the differential diagnosis between T-LBL and TdT^(+) T-lymphocyte-rich thymoma could be challenging, especially in the case of needle biopsy. &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39329449/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">DNA methylation as a new tool for the differential diagnosis between T-LBL and lymphocyte-rich thymoma</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39329449-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    T-lymphoblastic lymphoma (T-LBL) and thymoma are two rare primary tumors of the thymus deriving either from T-cell precursors or from thymic epithelial cells, respectively. Some thymoma subtypes (AB, B1, and B2) display numerous reactive terminal deoxynucleotidyl transferase-positive (TdT^(+)) T-cell precursors masking epithelial tumor cells. Therefore, the differential diagnosis between T-LBL and TdT^(+) T-lymphocyte-rich thymoma could be challenging, especially in the case of needle biopsy. &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39330692/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240927184334&amp;v=2.18.0.post9&#43;e462414">How Far Is the Nanocellulose Chip and Its Production in Reach? A Literature Survey</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39330692-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240927184334-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The slowdown of Moore&rsquo;s Law necessitates an exploration of novel computing methodologies, new materials, and advantages in chip design. Thus, carbon-based materials have promise for more energy-efficient computing systems in the future. Moreover, sustainability emerges as a new concern for the semiconductor industry. The production and recycling processes associated with current chips present huge environmental challenges. Electronic waste is a major problem, and sustainable solutions &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39330692/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">How Far Is the Nanocellulose Chip and Its Production in Reach? A Literature Survey</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39330692-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The slowdown of Moore&rsquo;s Law necessitates an exploration of novel computing methodologies, new materials, and advantages in chip design. Thus, carbon-based materials have promise for more energy-efficient computing systems in the future. Moreover, sustainability emerges as a new concern for the semiconductor industry. The production and recycling processes associated with current chips present huge environmental challenges. Electronic waste is a major problem, and sustainable solutions &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39330962/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240927184326&amp;v=2.18.0.post9&#43;e462414">Celebrating Public Health</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39330962-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240927184326-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39330962/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240928190141&amp;v=2.18.0.post9&#43;e462414">Celebrating Public Health</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39330962-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240928190141-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39330966/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240927184326&amp;v=2.18.0.post9&#43;e462414">Fractional Doses of Pneumococcal Conjugate Vaccine - A Noninferiority Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39330966-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240927184326-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In a three-dose schedule (two primary doses and a booster), 40% doses of PCV13 were noninferior to full doses for all included serotypes. Lower doses of PCV13 and PCV10 did not meet the criteria for noninferiority. (Funded by the Bill and Melinda Gates Foundation and others; ClinicalTrials.gov number, NCT03489018; Pan African Clinical Trial Registry number, PACTR202104717648755.). &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39330966/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&amp;fc=20211015124055&amp;ff=20240928190141&amp;v=2.18.0.post9&#43;e462414">Fractional Doses of Pneumococcal Conjugate Vaccine - A Noninferiority Trial</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39330966-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1lik-026y9bjre4xdq231bsa89bny4o2rfi-9wxqd8c31c6cqe-fc-20211015124055-ff-20240928190141-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: In a three-dose schedule (two primary doses and a booster), 40% doses of PCV13 were noninferior to full doses for all included serotypes. Lower doses of PCV13 and PCV10 did not meet the criteria for noninferiority. (Funded by the Bill and Melinda Gates Foundation and others; ClinicalTrials.gov number, NCT03489018; Pan African Clinical Trial Registry number, PACTR202104717648755.). &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39331066/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240927184334&amp;v=2.18.0.post9&#43;e462414">Reconstruction of severe acetabular defects (Paprosky type III A) in total hip arthroplasty using modular tantalum augments in combination with a cemented cup</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39331066-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240927184334-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: This study has demonstrated good mid-term (mean 4.5 years) clinical and radiological outcomes of modular tantalum TM augments in combination with a cemented cup for the reconstruction of major acetabular defects. Mean blood tantalum concentrations were increased in patients with stable tantalum implants compared to healthy &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39331066/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Reconstruction of severe acetabular defects (Paprosky type III A) in total hip arthroplasty using modular tantalum augments in combination with a cemented cup</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39331066-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: This study has demonstrated good mid-term (mean 4.5 years) clinical and radiological outcomes of modular tantalum TM augments in combination with a cemented cup for the reconstruction of major acetabular defects. Mean blood tantalum concentrations were increased in patients with stable tantalum implants compared to healthy &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39331123/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240927184334&amp;v=2.18.0.post9&#43;e462414">Discovery of BAY-405: An Azaindole-Based MAP4K1 Inhibitor for the Enhancement of T-Cell Immunity against Cancer</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39331123-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240927184334-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1) is a serine/threonine kinase that acts as an immune checkpoint downstream of T-cell receptor stimulation. MAP4K1 activity is enhanced by prostaglandin E2 (PGE2) and transforming growth factor beta (TGFβ), immune modulators commonly present in the tumor microenvironment. Therefore, its pharmacological inhibition is an attractive immuno-oncology concept for inducing therapeutic T-cell responses in cancer patients. Here, we &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39331123/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Discovery of BAY-405: An Azaindole-Based MAP4K1 Inhibitor for the Enhancement of T-Cell Immunity against Cancer</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39331123-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1) is a serine/threonine kinase that acts as an immune checkpoint downstream of T-cell receptor stimulation. MAP4K1 activity is enhanced by prostaglandin E2 (PGE2) and transforming growth factor beta (TGFβ), immune modulators commonly present in the tumor microenvironment. Therefore, its pharmacological inhibition is an attractive immuno-oncology concept for inducing therapeutic T-cell responses in cancer patients. Here, we &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39331528/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Long-term outcome of the Milano-HART strategy for high-risk medulloblastoma, including the impact of molecular subtype</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39331528-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSIONS: This strategy, partly adopted in the ongoing SIOPE protocol,confirmed improved EFS and OS over previously reported outcomes in all high-risk categories;SHH tumors appeared the most &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39331673/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">GPMelt: A hierarchical Gaussian process framework to explore the dark meltome of thermal proteome profiling experiments</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39331673-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Thermal proteome profiling (TPP) is a proteome wide technology that enables unbiased detection of protein drug interactions as well as changes in post-translational state of proteins between different biological conditions. Statistical analysis of temperature range TPP (TPP-TR) datasets relies on comparing protein melting curves, describing the amount of non-denatured proteins as a function of temperature, between different conditions (e.g. presence or absence of a drug). &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39331724/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=7603509&amp;fc=None&amp;ff=20240928190140&amp;v=2.18.0.post9&#43;e462414">Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39331724-utm-source-curl-utm-medium-rss-utm-campaign-journals-utm-content-7603509-fc-none-ff-20240928190140-v-2-18-0-post9-e462414/">
    
    
    
    
    
      
    
    No randomized trial has directly compared daratumumab and lenalidomide (D-R) maintenance therapy versus standard-of-care lenalidomide (R) alone post-transplant. Here, we report the primary results of the phase 3 AURIGA study evaluating D-R versus R maintenance in NDMM patients who were in ≥very good partial response, minimal residual disease (MRD; threshold 10-5) positive, and anti-CD38 naïve post-transplant. Patients were randomized 1:1 to D-R or R maintenance for up to 36 cycles. Two &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39331727/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Twin study identifies early immunological and metabolic dysregulation of CD8&lt;sup&gt;&#43;&lt;/sup&gt; T cells in multiple sclerosis</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39331727-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Multiple sclerosis (MS) is an inflammatory neurological disease of the central nervous system with a subclinical phase preceding frank neuroinflammation. CD8^(+) T cells are abundant within MS lesions, but their potential role in disease pathology remains unclear. Using high-throughput single-cell RNA sequencing and single-cell T cell receptor analysis, we compared CD8^(+) T cell clones from the blood and cerebrospinal fluid (CSF) of monozygotic twin pairs in which the cotwin had either no &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39332409/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Common variants increase risk for congenital diaphragmatic hernia within the context of de novo variants</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39332409-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Congenital diaphragmatic hernia (CDH) is a severe congenital anomaly often accompanied by other structural anomalies and/or neurobehavioral manifestations. Rare de novo protein-coding variants and copy-number variations contribute to CDH in the population. However, most individuals with CDH remain genetically undiagnosed. Here, we perform integrated de novo and common-variant analyses using 1,469 CDH individuals, including 1,064 child-parent trios and 6,133 ancestry-matched, unaffected &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39332586/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Integration of Transcriptomics, Proteomics and Loss-of-function Screening Reveals WEE1 as a Target for Combination with Dasatinib against Proneural Glioblastoma</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39332586-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Glioblastoma is characterized by a pronounced resistance to therapy with dismal prognosis. Transcriptomics classify glioblastoma into proneural (PN), mesenchymal (MES) and classical (CL) subtypes that show differential resistance to targeted therapies. The aim of this study was to provide a viable approach for identifying combination therapies in glioblastoma subtypes. Proteomics and phosphoproteomics were performed on dasatinib inhibited glioblastoma stem cells (GSCs) and complemented by &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39332691/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Role of the RNA binding protein IGF2BP1 in cancer multidrug resistance</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39332691-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The insulin-like growth factor-2 mRNA-binding protein 1 (IGF2BP1), a member of a conserved family of single-stranded RNA-binding proteins (IGF2BP1-3), is expressed in a broad range of fetal tissues, placenta and more than sixteen cancer types but only in a limited number of normal adult tissues. IGF2BP1is required for the transport from nucleus to cytoplasm of certain mRNAs that play essential roles in embryogenesis, carcinogenesis, and multidrug resistance (MDR), by affecting their &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39332710/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">DNA methylation profiling of salivary gland tumors supports and expands conventional classification</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39332710-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Tumors of the major and minor salivary gland histologically encompass a diverse and partly overlapping spectrum of frequently diagnostically challenging neoplasms. Despite recent advances in molecular testing and the identification of tumor-specific mutations or gene fusions, there is an unmet need to identify additional diagnostic biomarkers for entities lacking specific alterations. In this study, we collected a comprehensive cohort of 363 cases encompassing 20 different salivary gland &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39332820/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Breaking Strong Alkynyl-Phenyl Bonds: Poly(&lt;em&gt;para&lt;/em&gt;-phenylene ethynylene)s under Mechanical Stress</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39332820-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    Stronger chemical bonds withstand higher mechanical forces; thus, the rupture of single bonds is preferred over the rupture of double or triple bonds or aromatic rings. We investigated bond scission in poly(dialkyl-p-phenylene ethynylene)s (PPEs), a fully conjugated polymer. In a scale-bridging approach using electron-paramagnetic resonance spectroscopy and gel permeation chromatography of cryomilled samples, in combination with density functional theory calculations and &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39332899/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Early stopping versus continued retrievals after failed recanalization: associated factors and implications for outcome</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39332899-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    CONCLUSION: The probability of early stopping was higher in patients with clinical conditions associated with: a) Favorable prognosis and assumed lower impact of recanalization success on functional status, such as distal occlusions; and b) Unfavorable prognosis, such as higher age and reduced pre-stroke functional status. Adverse events during the procedure increased the probability of early stopping. The number of recanalization attempts did not increase the risk of unfavorable outcome &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39333300/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Thanks to the ABC reviewers in 2024</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39333300-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    No &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://pubmed.ncbi.nlm.nih.gov/39333498/?utm_source=curl&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&amp;fc=20220326224207&amp;ff=20240928190145&amp;v=2.18.0.post9&#43;e462414">Phosphoproteomics-directed manipulation reveals SEC22B as a hepatocellular signaling node governing metabolic actions of glucagon</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/pubmed-ncbi-nlm-nih-gov-39333498-utm-source-curl-utm-medium-rss-utm-campaign-pubmed-2-utm-content-1faks-2qokct8hsmoqp1bcrq4yzyumyomxmf0molsq3dfb1e9v-fc-20220326224207-ff-20240928190145-v-2-18-0-post9-/">
    
    
    
    
    
      
    
    The peptide hormone glucagon is a fundamental metabolic regulator that is also being considered as a pharmacotherapeutic option for obesity and type 2 diabetes. Despite this, we know very little regarding how glucagon exerts its pleiotropic metabolic actions. Given that the liver is a chief site of action, we performed in situ time-resolved liver phosphoproteomics to reveal glucagon signaling nodes. Through pathway analysis of the thousands of phosphopeptides identified, we reveal &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/OyTL3i4rv">新冠疫苗或提高肿瘤患者总体生存。今天Biocentury讲到了2024年ESMO（欧洲肿瘤学会年会）一个非常有意思的来自MD Anderson的研究（摘要995 MO），该研究发现接种...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-oytl3i4rv/">
    
    
    
    
    
      
    
    新冠疫苗或提高肿瘤患者总体生存。今天Biocentury讲到了2024年ESMO（欧洲肿瘤学会年会）一个非常有意思的来自MD Anderson的研究（摘要995 MO），该研究发现接种了新冠COVID mRNA疫苗的转移恶性黑色素瘤患者总体生存率（OS）提高、疾病进展延缓（当然，统计分析的时候要除外COVID mRNA减少患者发生COVID对患者预后的影响）。研究进一步发现接种COVID-19 mRNA疫苗非小细胞肺癌患者（NSCLC）在接种疫苗100天内做穿刺活检，疫苗接种者肿瘤组织PD-L1表达上调，因此对PD-1/PD-L1拮抗剂应答更好。<!-- raw HTML omitted --><!-- raw HTML omitted -->我上一个工作研究mRNA疫苗在新冠COVID和HIV中的应用。2022年底，Merck和Moderna报道了其肿瘤治疗mRNA疫苗mRNA-4157和Keytruda联合治疗将III/IV期恶性黑色素瘤死亡和复发降低44%的2期临床试验结果，这一结果在2023年AACR上被进一步报道（&lt;a &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1251560221/OyZyNfMxa">美国卫生部又开始免费发放COVID检测试剂盒了，每家可以领4个，USPS免费邮寄网站链接：网页链接 - 转发 @子陵在听歌:&amp;ensp;重要的信息。美国夏季经历了一个COVID...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1251560221-oyzynfmxa/">
    
    
    
    
    
      
    
    美国卫生部又开始免费发放COVID检测试剂盒了，每家可以领4个，USPS免费邮寄网站链接：<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->网页链接<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --> - 转发 <!-- raw HTML omitted -->@子陵在听歌<!-- raw HTML omitted -->: 重要的信息。美国夏季经历了一个COVID疫情小高峰，虽然最近COVID疫情有所缓解，但白宫宣布自9月25日将重新开始免费向美国居民发放检测试剂盒，每家（household）可以领取4个。领取网站与原来一样：&lt;a &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OyXEmieLx">🔻说真的，日本人选谁都是乐子。🔻比如，这是性转东条二等兵魔怔人高市早苗演唱的《Rusty Nail》#石破茂将出任日本首相##热门视频# 包容万物恒河水的微博视...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oyxemielx/">
    
    
    
    
    
      
    
    🔻说真的，日本人选谁都是乐子。<!-- raw HTML omitted -->🔻比如，这是性转东条二等兵魔怔人高市早苗演唱的《Rusty Nail》<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#石破茂将出任日本首相#<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OyXGIhJ3k">🔻莫伊谢耶夫芭蕾舞团演员的漂浮舞蹈技巧。#热门视频# 包容万物恒河水的微博视频</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oyxgihj3k/">
    
    
    
    
    
      
    
    🔻莫伊谢耶夫芭蕾舞团演员的漂浮舞蹈技巧。<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#热门视频#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->包容万物恒河水的微博视频<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted -->&lt;div style=&ldquo;clear: &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OyXIjwvVk">🔻美国海岸警卫队在海伦飓风来临之前，从一条失控帆船上救了一个人和他的狗。🔻via uscoastguard#热门视频# 包容万物恒河水的微博视频</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oyxijwvvk/">
    
    
    
    
    
      
    
    🔻美国海岸警卫队在海伦飓风来临之前，从一条失控帆船上救了一个人和他的狗。<!-- raw HTML omitted -->🔻via uscoastguard<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#热门视频#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->包容万物恒河水的微博视频<!-- raw HTML omitted --><!-- raw HTML omitted --> &lt;br &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OyXJgCn65">🔻麻生太郎是不是玩不起？#石破茂将出任日本首相##热门视频# 包容万物恒河水的微博视频</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oyxjgcn65/">
    
    
    
    
    
      
    
    🔻麻生太郎是不是玩不起？<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#石破茂将出任日本首相#<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#热门视频#<!-- raw HTML omitted --><!-- raw HTML omitted --> &lt;a href=&ldquo;<a href="https://video.weibo">https://video.weibo</a>. &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OyXJjFbBQ">🔻在🇰🇵朝鲜东海边咸兴附近风景秀丽的马庄海水浴场再次向外国游客开放。🔻via vk#热门视频# 包容万物恒河水的微博视频</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oyxjjfbbq/">
    
    
    
    
    
      
    
    🔻在🇰🇵朝鲜东海边咸兴附近风景秀丽的马庄海水浴场再次向外国游客开放。<!-- raw HTML omitted -->🔻via vk<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#热门视频#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->包容万物恒河水的微博视频<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted -->&lt;div &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OyXKDbs4n">🔻别这样，哥们儿#A股正从反弹走向反转# [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oyxkdbs4n/">
    
    
    
    
    
      
    
    🔻别这样，哥们儿<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#A股正从反弹走向反转#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OyXLH6h4P">🔻？没有啊？#武汉震感# [图片][图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oyxlh6h4p/">
    
    
    
    
    
      
    
    🔻？没有啊？<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#武汉震感#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --><!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OyXOz1GAQ">🔻编目里也没看到。#武汉震感# [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oyxoz1gaq/">
    
    
    
    
    
      
    
    🔻编目里也没看到。<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#武汉震感#<!-- raw HTML omitted --><!-- raw HTML omitted --> <!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OyXW8vtct">🔻加藤胜信今天与公开支持他竞选自民党候选人的议员们共进午餐，吃了一顿传统的咖喱猪排饭，吃饭的一共有 20 人。🔻在第一轮投票中，加藤只得到了 16 票，这...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oyxw8vtct/">
    
    
    
    
    
      
    
    🔻加藤胜信今天与公开支持他竞选自民党候选人的议员们共进午餐，吃了一顿传统的咖喱猪排饭，吃饭的一共有 20 人。<!-- raw HTML omitted -->🔻在第一轮投票中，加藤只得到了 16 票，这意味着有 4 个吃了咖喱猪排饭的人背叛了他。<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->#石破茂将出任日本首相#<!-- raw HTML omitted --><!-- raw HTML omitted --> &lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax2.sinaimg.cn/large/639b1bfbly1hu2m3kx3cxj20qo1bdk2g.jpg%22">https://tvax2.sinaimg.cn/large/639b1bfbly1hu2m3kx3cxj20qo1bdk2g.jpg&quot;</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/1671109627/OyXXack5n">又懂完咯～是不是老马没开源的都是动画啊？//@马一龙无敌克拉斯:回复@十五今天看书了吗:火箭没绕流啊，穿越机可以随意的攀升俯拍还能在火箭下面仰拍，居然也没受...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-1671109627-oyxxack5n/">
    
    
    
    
    
      
    
    又懂完咯～是不是老马没开源的都是动画啊？//<!-- raw HTML omitted -->@马一龙无敌克拉斯<!-- raw HTML omitted -->:回复<!-- raw HTML omitted -->@十五今天看书了吗<!-- raw HTML omitted -->:火箭没绕流啊，穿越机可以随意的攀升俯拍还能在火箭下面仰拍，居然也没受到绕流影响，这是什么nb设备？而且爆炸瞬间的烟雾，感觉很假… 而且整体的画面一丝噪点都没有，甚至爆炸都没，太扯淡了//<!-- raw HTML omitted -->@马一龙无敌克拉斯<!-- raw HTML omitted -->:显然就是动画//&lt;a href=&ldquo;<a href="https://weibo.com/n/%E8%A2%AB%E5%8A%A8%E8%A2%AB%E5%8A%25">https://weibo.com/n/%E8%A2%AB%E5%8A%A8%E8%A2%AB%E5%8A%</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OyWrcFcU6">久保史绪里 via.nogizaka_goods [图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-oywrcfcu6/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted --> via.nogizaka_goods <!-- raw HTML omitted --> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OyX1MzlBn">久保史绪里 via.緒行记fb [图片][图片]</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-oyx1mzlbn/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted --> via.緒行记fb <!-- raw HTML omitted -->&lt;img style=&quot;&quot; src=&ldquo;<a href="https://tvax1.sinaimg.cn/large/006z6nxLgy1hu2i4b3jwsj30u00k">https://tvax1.sinaimg.cn/large/006z6nxLgy1hu2i4b3jwsj30u00k</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OyYVAwBPh">久保史绪里#久保史绪里手机博# 2024.09.25 11:55「欸嘿嘿」早上好〜想做的事情、必须要做的事情虽然堆积如山，但我打算好好利用时间逐一整理…！！早上开始就吃...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-oyyvawbph/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OyYWth7y5">久保史绪里#久保史绪里手机博# 2024.09.25 11:56(补)「呜呼呼」DARS！请一定要看看广告哦〜！！！一直在跳舞☺︎休息室里我一直跟某个女孩一直待在一起。大概就...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-oyywth7y5/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;a href=&ldquo;<a href="https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D%9A%23&amp;amp;isnewpa">https://m.weibo.cn/search?containerid=231522type%3D1%26t%3D10%26q%3D%23%E4%B9%85%E4%BF%9D%E5%8F%B2%E7%BB%AA%E9%87%8C%E6%89%8B%E6%9C%BA%E5%8D%9A%23&amp;amp;isnewpa</a> &hellip;
    </a>
  </div>
</section>

<section class="article-list">
  <h1><a href="https://weibo.com/6015489225/OyYZz1sX9">久保史绪里#shiorigram# 棒球少女鹫尾@ comic鹫尾希望保持乐天漫画今天发售…🎉终于要发售了…！！请一定要入手👀乃木坂46ANN的栏目变成漫画…像是虚无缥缈...</a></h1>
  <div class="date-author">
    
    <span class="date">2024-09-27</span>
  </div>
  <div class="summary">
    <a href="/post/weibo-com-6015489225-oyyzz1sx9/">
    
    
    
    
    
      
    
    <!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->久保史绪里<!-- raw HTML omitted --><!-- raw HTML omitted --><!-- raw HTML omitted -->&lt;span &hellip;
    </a>
  </div>
</section>

</main>
</div>

<script async src="//yihui.name/js/center-img.js"></script>

<footer>

<div class="footer">
  <ul class="menu">
    
    <li><a href="/"><span data-hover="Home">Home</span></a></li>
    
    <li><a href="/about/"><span data-hover="About">About</span></a></li>
    
    <li><a href="/archives/"><span data-hover="Archive">Archive</span></a></li>
    
    <li><a href="/contributor/"><span data-hover="Contributor">Contributor</span></a></li>
    
    <li><a href="/index.xml"><span data-hover="Subscribe">Subscribe</span></a></li>
    
  </ul>
  
  <div class="copyright">© <a href="https://rainoffallingstar.github.io">Fallingstar</a> 2023 | <a href="https://github.com/rainoffallingstar">Github</a></div>
  
</div>
</footer>







</body>
</html>

